70 years of metformin use. Success and achievements
https://doi.org/10.62751/2713-0177-2024-5-2-19
Abstract
The first mention of metformin appeared about 100 years ago. Since then, the evolution of opinions about metformin has undergone significant changes. In recent decades, the active use of this drug has revealed a wide range of positive properties of metformin both in relation to metabolic health and completely unexpected aspects of longevity and quality of life. This review focuses on the current properties of metformin and the prospects for increasing the popularity of this drug among patients and medical professionals in terms of potential public health benefits.
About the Authors
A. S. Teplova
Pirogov Russian National Research Medical University
Anna S. Teplova, assistant of the department of endocrinology medical faculty
Moscow
T. L. Bogacheva
Pirogov Russian National Research Medical University
Tatiana L. Bogacheva, assistant of the department of endocrinology medical faculty
Moscow
A. E. Timofeeva
Pirogov Russian National Research Medical University
Anastasia E. Timofeeva, student of the faculty of general medicine
Moscow
D. S. Stegacheva
Pirogov Russian National Research Medical University
Dina S. Stegacheva, student of the faculty of general medicine
Moscow
References
1. Юбилей МЕТФОРМИНА: 2007 год – 50 лет применения. Сахарный диабет. 2007; 10(4):71–71. https://doi.org/10.14341/2072–0351–5872
2. Дедов И. И., Шестакова М. В., Майоров А. Ю., Мокрышева Н. Г., Андреева Е. Н., Безлепкина О. Б. et al. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. 11-й выпуск. Сахарный диабет. 2023;26(2S):1–157. https://doi.org/10.14341/DM13042
3. American Diabetes Association Professional Practice Committee: 15 Management of diabetes in pregnancy: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45:232–43. doi: 10.2337/dc22-S015
4. Diabetes Canada Clinical Practice Guidelines Expert Committee, D. S. Feig, H. Berger, L. Donovan, A. Godbout, T. Kader, E. Keely et al. Diabetes and pregnancy. Can. J. Diabetes 42, 255–82 (2018). 10.1016/j.jcjd.2017.10.038
5. Sciacca L, Bianchi C, Burlina S, Formoso G, Manicardi E, Sculli MA, et al. Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: metformin use in pregnancy. Acta Diabetol. 2023; 60:1421–37. doi: 10.1007/S00592-023-02137-5/TABLES/15
6. Nguyen L, Chan SY, Teo AKK. Metformin from mother to unborn child – Are there unwarranted effects? EBioMedicine. 2018 Sep;35:394–404. doi: 10.1016/j.ebiom.2018.08.047
7. LaMoia TE, Shulman GI. Cellular and Molecular Mechanisms of Metformin Action. Endocr Rev. 2021 Jan 28;42(1):77–96. doi: 10.1210/endrev/bnaa023
8. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019 Oct;15(10):569–589. doi: 10.1038/s41574-019-0242-2
9. Fadini GP, Albiero M, Menegazzo L, de Kreutzenberg SV, Avogaro A. The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-t reated patients. Diabetes Obes Metab. 2012;14:518–522. doi: 10.1111/j.1463-1326.2011.01550.x
10. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care. 2001;24:489–494. doi: 10.2337/diacare.24.3.489
11. Yi F, Sun J, Lim GE, Fantus IG, Brubaker PL, Jin T. Cross talk between the insulin and Wnt signaling pathways: evidence from intestinal endocrine L cells. Endocrinology. 2008; 149:2341–2351. doi: 10.1210/en.2007-1142
12. Huang Y, Lou X, Jiang C, Ji X, Tao X, Sun J, Bao Z. Gut microbiota is correlated with gastrointestinal adverse events of metformin in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2022 Nov 17; 13:1044030. doi: 10.3389/fendo.2022.1044030
13. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016 Mar;59(3):426–35. doi: 10.1007/s00125-015-3844-9
14. Shu Y, Li W, Hu Q, Xiong D. Bibliometrics and visual analysis of metformin and gut microbiota from 2012 to 2022: A systematic review. Medicine (Baltimore). 2023 Dec 15;102(50): e36478. doi: 10.1097/MD.0000000000036478
15. Pavlo Petakh, Kamyshna I, Kamyshnyi A. Effects of metformin on the gut microbiota: A systematic review. Mol Metab. 2023 Nov;77:101805. doi: 10.1016/j.molmet.2023.101805
16. Vallianou NG, Stratigou T, Tsagarakis S. Metformin and gut microbiota: their interactions and their impact on diabetes. Hormones (Athens). 2019 Jun;18(2):141–144. doi: 10.1007/s42000-019-00093-w
17. Zhou C, Peng B, Qin Z, Zhu W, Guo C. Metformin attenuates LPS-induced neuronal injury and cognitive impairments by blocking NF-κB pathway. BMC Neurosci. 2021 Nov 26;22(1):73. doi: 10.1186/s12868-021-00678-5
18. Huang H, Lee SH, Sousa-L ima I, et al. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. J Clin Invest. 2018; 128:5335–5350. doi: 10.1172/JCI63562
19. Tang X, Li J, Xiang W, et al. Metformin increases hepatic leptin receptor and decreases steatosis in mice. J Endocrinol. 2016; 230:227–237. doi: 10.1530/JOE-16-0142
20. Pinyopornpanish K, Leerapun A, Pinyopornpanish K, Chattipakorn N. Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels. Gut Liver. 2021 Nov 15;15(6):827–840. doi: 10.5009/gnl20367
21. Li YL, Li XQ, Wang YD, Shen C, Zhao CY. Metformin alleviates inflammatory response in non-alcoholic steatohepatitis by restraining signal transducer and activator of transcription 3-mediated autophagy inhibition in vitro and in vivo. Biochem Biophys Res Commun. 2019; 513:64–72. doi: 10.1016/j.bbrc.2019.03.077
22. Løvvik TS, Carlsen SM, Salvesen Ø, Steffensen B, Bixo M, Gómez-Real F, Lønnebotn M, Hestvold KV, Zabielska R, Hirschberg AL, Trouva A, Thorarinsdottir S, Hjelle S, Berg AH, Andræ F, Poromaa IS, Mohlin J, Underdal M, Vanky E. Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019 Apr;7(4):256–266. doi: 10.1016/S2213-8587(19)30002-6
23. Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne). 2020 Apr 16; 11:191. doi: 10.3389/fendo.2020.00191
24. Chen F, Wei G, Wang Y, Liu T, Huang T, Wei Q, Ma G, Wang D. Risk factors for depression in elderly diabetic patients and the effect of metformin on the condition. BMC Public Health. 2019 Aug 7;19(1):1063. doi: 10.1186/s12889-019-7392-y
25. Pomilio C, Pérez NG, Calandri I, Crivelli L, Allegri R; ADNI Alzheimer’s Disease Neuroimaging Initiative; Sevlever G, Saravia F. Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study. Geroscience. 2022 Jun;44(3):1791–1805. doi: 10.1007/s11357-022-00568-6
26. Mohammed I, Hollenberg MD, Ding H, Triggle CR. A Critical Review of the Evidence That Metformin Is a Putative Anti-A ging Drug That Enhances Healthspan and Extends Lifespan. Front Endocrinol (Lausanne). 2021 Aug 5;12:718942. doi: 10.3389/fendo.2021.718942
27. Mohammed I, Hollenberg MD, Ding H, Triggle CR. A Critical Review of the Evidence That Metformin Is a Putative Anti-A ging Drug That Enhances Healthspan and Extends Lifespan. Front Endocrinol (Lausanne). 2021 Aug 5;12:718942. doi: 10.3389/fendo.2021.718942
Review
For citations:
Teplova A.S., Bogacheva T.L., Timofeeva A.E., Stegacheva D.S. 70 years of metformin use. Success and achievements. FOCUS. Endocrinology. 2024;5(2):62-65. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-2-19
Views:
264
Email this article 